Moderna stock is trading -37.57% below its average target price of $57.32 after marking a 8.5% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of hold and target prices ranging from $25.0 to $212.0 per share.
The stock has an above average percentage of its shares sold short at 13.9%, and a short ratio of 3.29. The company's insiders own 9.6% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.8% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Vanguard Group Inc | 10% | 40,323,750 | $1,443,187,049 |
| 2024-12-31 | Baillie Gifford and Company | 10% | 38,889,571 | $1,391,857,781 |
| 2024-12-31 | Blackrock Inc. | 7% | 25,791,947 | $923,093,806 |
| 2024-12-31 | FMR, LLC | 5% | 18,664,634 | $668,007,267 |
| 2024-12-31 | State Street Corporation | 5% | 17,577,236 | $629,089,292 |
| 2024-12-31 | Theleme Partners LLP | 2% | 7,306,861 | $261,512,561 |
| 2024-12-31 | Geode Capital Management, LLC | 2% | 7,241,354 | $259,168,066 |
| 2024-12-31 | UBS Group AG | 1% | 5,073,371 | $181,575,952 |
| 2024-12-31 | Invesco Ltd. | 1% | 5,006,462 | $179,181,279 |
| 2024-12-31 | Flagship Pioneering Inc. | 1% | 4,632,149 | $165,784,616 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Moderna.
